Skip to content

Phase II clinical study using isotoxic dose prescription to increase the dose of carbon ion radiotherapy in LA-NSCLC

Phase II clinical study using isotoxic dose prescription to increase the dose of carbon ion radiotherapy in LA-NSCLC

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054173
Enrollment
Unknown
Registered
2021-12-10
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Therapy group :Carbon ion radiotherapy

Sponsors

Wuwei Tumor Hospital Heavy Ion Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 and 9.5 g/dL; white blood cell count >= 3000/ml; platelet count >= 100,000 /mL; 8. Good physical condition, ECOG 2; 9. Expected survival >= 6 months; 10. Informed consent was signed by the patient or legal representative before radiotherapy.

Exclusion criteria

Exclusion criteria: 1. Patients cant hold their positions for more than 30 minutes; 2. Tumor progression extensively involving the pleura and cancerous pleural effusion; 3. Lose more than 20% of body weight within six months; 4. During pregnancy(confirmed by serum or urine beta-HCG test) or lactation; 5. Drug abuse or alcohol dependence; 6. AIDS; 7. With uncontrolled systemic or pulmonary or cardiac disease; 8. With serious comorbidities that preclude the successful implementation of the trial protocol, including uncontrolled comorbidities (pulmonary insufficiency, cardiovascular, lung, liver, kidney, diabetes, etc.), addiction and/or mental illness; 9. Implantation of a pacemaker or other metal prosthesis can be enough to affect the recipient of radiation therapy; 10. Patients with poor compliance, including those who may not be able to complete treatment plans or receive required follow-up and examinations; 11. has a history of other malignancies(skin cancer and stage 0 cervical cancer have been cured are excluded); 12. Systemic immunotherapy or corticosteroid therapy; 13. Serum creatinine clearance < 30 mL/minutes; 14. There are contraindications to radiation therapy; 15. Participated in clinical trials of other drugs within 30 days prior to enrollment in this trial; 16. Incapacity for civil conduct or limited capacity for civil conduct; 17. Any medical history that in the investigator's judgment may interfere with trial results or increase patient risk; 18. Any conditions that the physician deems inappropriate for participation in the trial.

Design outcomes

Secondary

MeasureTime frame
Progression-Free Survival;Overall Survival;

Primary

MeasureTime frame
Local control rate;Toxic and side effect;

Countries

Chian

Contacts

Public ContactZhang Yanshan

Wuwei Tumor Hospital Heavy Ion Center

13830510999@163.com+86 13830510999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026